The New England journal of medicine
-
Editorial Comment
Drug Regulation in the Era of Individualized Therapies.
-
Randomized Controlled Trial Multicenter Study
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.
It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. ⋯ In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding. (Funded by the Netherlands Organization for Health Research and Development; POPular Genetics ClinicalTrials.gov number, NCT01761786; Netherlands Trial Register number, NL2872.).